This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Mcneeley, P A Articles by Linnik, M D Search for Related Content PubMed PubMed Citation Articles by Mcneeley, P A Articles by Linnik, M D Social Bookmarking                         What's this?

Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients

G M Iverson

La Jolla Pharmaceutical Company, San Diego, California, USA

R A Furie

North Shore University Hospital, N.Y.U. School of Medicine, Manhasset, New York, USA

J M Cash

The Cleveland Clinic Foundation, Cleveland, Ohio, USA

M E Cronin

Medical College of Wisconsin, Milwaukee, Wisconsin, USA

R S Katz

Chicago, Illinois, USA

M H Weisman

Cedars-Sinai Medical Center, Los Angeles, California, USA

C Aranow

State University of New York-Downstate, Brooklyn, New York, USA

M D Linnik

La Jolla Pharmaceutical Co., 6455 Nancy Ridge Drive, San Diego, CA 92121, USA. linnik{at}ljpc.com

Five prospective clinical studies in lupus patients have shown that LJP 394 can reduce circulating anti-dsDNA antibody levels without causing generalized immunosuppression. The compound is currently being evaluated in a phase III clinical trial for the prevention of renal flares in patients with high-affinity antibodies to LJP 394 and a history of lupus nephritis. The current study analyzed the affinity of patient IgG for LJP 394 prior to and following 4 months of treatment with LJP 394 to determine if pretreatment affinity influenced pharmacodynamic response. Patient serum samples from a multicenter, double-blind, placebo-controlled trial were evaluated prior to and following 4 months of weekly, biweekly or monthly treatment with placebo (n=9) or weekly treatment with 10 mg LJP 394 (n=6) or 50 mg LJP 394 (n=4). After treatment there was a dose-dependent reduction in affinity in the 10 mg/week and 50 mg/week groups (P < 0.05 and P < 0.01, respectively), whereas the placebo group was unchanged. This study demonstrates that weekly treatment with LJP 394 produces a dose-dependent reduction in titer-weighted average affinity. These results suggest it may be possible to use an affinity assay to define prospectively patients that are most likely to exhibit the desired pharmacodynamic response to LJP 394.

Key Words: lupus • nephritis • LJP 394 • affinity

Lupus, Vol. 10, No. 8, 526-532 (2001)
DOI: 10.1191/096120301701549642


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. D. Linnik, A. M. O'Rourke, and M. A. Crowther Pharmacokinetics of High-Dose Abetimus Sodium in Normal Subjects With Specific Assessment of Effect on Coagulation J. Clin. Pharmacol., August 1, 2008; 48(8): 909 - 918. [Abstract] [Full Text] [PDF]

				C Iking-Konert, S Stocks, F Weinsberg, R Engelbrecht, E Bleck, A Perniok, R Fischer-Betz, S Pincus, L Nardone, and M Schneider First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104 Ann Rheum Dis, September 1, 2004; 63(9): 1104 - 1112. [Abstract] [Full Text] [PDF]

				D J Wallace and J A Tumlin LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus Lupus, May 1, 2004; 13(5): 323 - 327. [Abstract] [PDF]

				J T Merrill LJP 1082: a toleragen for Hughes syndrome Lupus, May 1, 2004; 13(5): 335 - 338. [Abstract] [PDF]

				V Strand, C Aranow, M H Cardiel, D Alarcon-Segovia, R Furie, Y Sherrer, J Tumlin, D J Wallace, LJP 394 Investigator Consortium, and B Crawford Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo Lupus, September 1, 2003; 12(9): 677 - 686. [Abstract] [PDF]

				M Linnik, N A Staines, J Berden, and D A Isenberg Workshop report on some new ideas about the treatment of systemic lupus erythematosus Lupus, December 1, 2002; 11(12): 793 - 796. [Abstract] [PDF]

				D Alarcon-Segovia The recovery of self tolerance in SLE Lupus, August 1, 2001; 10(8): 521 - 522. [PDF]